Study 301 | Study 305/EMBRACE | |||
---|---|---|---|---|
Stratified by treatment group | Not stratified | Stratified by treatment group | Not stratified | |
Compared with all othera subjects | ||||
Patients, n | 1102 | 762 | ||
HR (95 % CI) | 1.98 (1.71, 2.29) | 1.96 (1.70, 2.27) | 2.25 (1.79, 2.83) | 2.27 (1.80, 2.85) |
Wald p value | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Compared with those whose disease progressed due to an increase in the size of pre-existing lesion(s) | ||||
Patients, n | 663 | 469 | ||
HR (95 % CI) | 1.81 (1.54, 2.14) | 1.80 (1.53, 2.13) | 2.09 (1.63, 2.68) | 2.12 (1.65, 2.72) |
Wald p value | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Compared with those with no reported disease progressionb | ||||
Patients, n | 859 | 500 | ||
HR (95 % CI) | 2.20 (1.88, 2.57) | 2.16 (1.85, 2.53) | 2.61 (2.03, 3.37) | 2.60 (2.02, 3.34) |
Wald p value | <0.0001 | <0.0001 | <0.0001 | <0.0001 |